,,iv  #aag? ,,congress  #a/ ,session    
,h4 ,,res4 #cdi  ,,9 ,,! ,,h\se ,,(     
,,repres5tatives  ,april #bb1 #bjba,mrs4
 ,trahan 7= h]self1 ,ms4 ,blunt ,ro*e/]1
 ,mr4 ,fitzpatrick1 ,mr4 ,soto1 ,mr4    
,suozzi1 ,mr4 ,cleav]1 ,mr4 ,trone1 ,mr4
 ,lyn*1 ,ms4 ,dean1 ,ms4 ,jacobs (      
,cali=nia1 ,ms4 ,spanb]g]1 ,ms4 ,ku/]1  
,ms4 ,scanlon1 ,mr4 ,pappas1 ,mr4       
,mc,kinley1 ,ms4 ,t5ney1 ,mr4 ,curtis1  
,mr4 ,ru!r=d1 ,ms4 ,/ev5s1 ,mr4 ,y>mu?1 
,mr4 ,cicill9e1 ,mr4 ,grijalva1 ,mr4    
,au*9closs1 ,mr4 ,amodei1 ,mr4 ,c>bajal1
 & ,ms4 ,cl>k ( ,massa*usetts7 submitt$ 
! foll[+ resolution2 :i* 0 ref]r$ to !  
,committee on ,ov]sight & ,re=m         
,,resolution  ,support+ ! goals (       
,ov]dose ,aw>5ess ,day by l[]+ ! ,unit$ 
,/ates flag to half-/aff on all ,f$]al  
build+s ! #ca/ day ( ,augu/ ea* ye>4    
,:]eas m ?an #gej1jjj individuals 9 !   
,unit$ ,/ates h di$ f a drug ov]dose    
s9ce #aiii2 ,:]eas sub/ance use disord] 
& drug ov]dose affect all socioeconomic 
gr\ps1 racial & e?nic gr\ps1            

geographical regions1 & ages2 ,:]eas    
sub/ance use disord] is a *ronic disease
 & recogniz+ x z su* decreases /igma &  
ackn[l$ges t sub/ance use may be beyond 
an individual's control2 ,:]eas ov]dose 
dea?s are prev5table1 & lives c be sav$ 
?r\gh aw>5ess1 prev5tion1 int]v5tion1   
treatm5t1 & recov]y support2 ,:]eas     
ov]dose dea?s claim$ m ?an #ha1jjj      
,am]ican lives la/ ye>1 & ! ,,covid-#ai 
p&emic has contribut$ to ! accel]ation (
 ov]dose dea?s2 ,:]eas communities      
across ! ,nation h be5 pa9$ by sub/ance 
use disord] ?r\gh ! premature loss (    
lives & ! /igma associat$ ) drug-relat$ 
fatalities2 & ,:]eas num]\s ,/ates      
across ! ,nation h l[]$ _! ,/ate flags 9
 recognition ( ,ov]dose ,aw>5ess ,day3  
,n[1 !re=e1 be x ,t ! ,h\se (           
,repres5tatives supports ! recognition (
 ,ov]dose ,aw>5ess ,day 9 ! ,unit$      
,/ates ( ,am]ica & t ,f$]al build+s !re9
 be enc\rag$ to l[] _! flags to         
half-/aff to support aw>5ess ( ov]doses4